echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chinese pharmaceutical subsidiary vildagliptin tablets obtained drug registration certificate

    Chinese pharmaceutical subsidiary vildagliptin tablets obtained drug registration certificate

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 13, China Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary General Sanyo received a "drug registration certificate" for vildagliptin tablets approved and issued by the State Drug Administration for the treatment of type 2 diabetes


    On September 20, 2019, General Sanyo submitted the drug registration application to the State Food and Drug Administration and was accepted


    The drug was developed by Novartis and applied for marketing in the EU for the first time on September 26, 2007, with a specification of 50 mg and a trade name of Galvus®; at present, vildagliptin tablets have been approved for import and marketing in China


    The drug is suitable for the treatment of type 2 diabetes


    According to the data query on the website of the State Food and Drug Administration, up to now, the drug is owned by Qilu Pharmaceutical Co.


    As of the disclosure date of this announcement, GM Sanyo has invested approximately RMB 17 million in the drug R&D project (unaudited)


    According to the PDB database sample hospital drug sales statistics, the total sales amount of the drug sample hospital in 2020 is about 90 million yuan


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.